Page last updated: 2024-08-25

rosiglitazone and Cutaneous T-Cell Lymphoma

rosiglitazone has been researched along with Cutaneous T-Cell Lymphoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Greer, JP; Koyama, T; Sepmeyer, JA; Zic, JA	1

Trials

1 trial(s) available for rosiglitazone and Cutaneous T-Cell Lymphoma

Article	Year
Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:4 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Risk Assessment; Rosiglitazone; Single-Blind Method; Survival Analysis; Tetrahydronaphthalenes; Thiazolidinediones; Treatment Outcome	2007

Article

Year

Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.

Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:4

Topics: Aged; Anticarcinogenic Agents; Bexarotene; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Risk Assessment; Rosiglitazone; Single-Blind Method; Survival Analysis; Tetrahydronaphthalenes; Thiazolidinediones; Treatment Outcome

2007